HOME

. September 2016 Edition

fear-color

 Lead Article:

IN YOUR FACE RISK

“Oh, so you’re an angel investor. Isn’t that risky?” I hear such drivel all the time. Are people afraid of outsized returns? Or perhaps they don’t understand risk, don’t know how to measure it, or how to take control of it. Yet all that is quite easily done and it’s a real charge to play the game using a Monte Carlo simulation.

READ FULL NEWSLETTER:

PDF Version

WEB Version – Mobile Friendly

.

.

 

.

. May 2016 Edition

Cancer Treatment from MS Office

Lead Article:

CANCER STOPPER

A protein, CRR9, serves as a nexus for tumor cell survival. It’s located on the cell surface, making it an accessible drug target. By developing antibodies to the CRR9 protein, Essential Biotechnology has devised a method to kill therapy-resistant tumors.

READ FULL NEWSLETTER:

PDF Version

WEB Version – Mobile Friendly

.

.

.

 .February 2016 Edition

1989400_orig2

Lead Article:

TOO MANY FOUNDERS

A new company is born. It’s short on cash and long on tasks. Excited and talented founders gather together. Too many affect the success of the company and the happiness of the owners. Too many heighten dilution’s effect on the financial results that the founders may achieve personally.

READ FULL NEWSLETTER:

PDF Version

WEB Version – Mobile Friendly

.

.

.

.

.October 2015 Edition

 

Light Bulb

Lead Article:

APPLESAUCE AND APPLE

The students who began college this past fall have a forty percent chance of graduating in four years, and a seventy percent chance of graduating in six. They are all too keenly aware of how easily a sophisticated algorithm can replace human beings in the performance of even high-tech tasks. They are more interested in money than in love.

READ FULL NEWSLETTER:

PDF version

WEB version – Beta 1.0

WEB version – Beta 2.0

.

.

.

.May 2015 Edition

Pidgeonholes from MS Office

Lead Article:

RECOGNIZE THE PIGEONHOLES

Did we botch the launch of HealthCare.gov because our leaders are qualified to judge the capability of the technical contractors, or because they are not?

Read full Newsletter – PDF

.

.

.

.

.

.February 2015 Edition

Twenty Questions

Lead Article:

TWENTY QUESTIONS YOU WILL BE ASKED BY VENTURE CAPITALISTS

(If You Get That Far)

A key difference between the game “20 questions” and the venture capital interview is that you, the interviewee, don’t get to answer the questions with a simple “yes” or “no.” So, in order to help you prepare, outlined below are 20 questions that venture capitalists most frequently ask entrepreneurs.

Read full Newsletter – PDF 

.

.

.

.

.

November 2014 Edition

Illinois Heating Up 500

Lead Article:

ILLINOIS HEATING UP

Nearly $7.5B Invested – 1000 Deals

The Illinois startup scene has been getting bigger.  Pritzker Group Venture Capital topped the list of active investors, with more than 35 companies focused on the tech sector. Some include CleversafeGogo (which had its IPO in 2013), and Sittercity. They’re followed by Lightbank and Chicago Ventures, both having  more than 20 companies each . ..

Read full Newsletter – PDF

.

.

.

.

August 2014 Edition

Zombie for Archives

Lead Article:

BEING ANALOG IN A DIGITAL WORLD

Aristotle said, “We are what we repeatedly do.” Athletes call this phenomenon muscle memory,” Neuroscientists have a more interesting name for it: “Zombie Systems,” which is what happens when actions occur without conscious thought . . .

Read full Newsletter – PDF

.

.

.

 

 ..

May 2014 Edition

DSC_5954C

Lead Article:

ARISE 2.0

Whadaya think happens when 15,000 people get behind the entrepreneurs in their own neighborhood? Good things—that’s what happens! Energy. Enthusiasm. Stuff gets done! Lemme tell you about it . . .

Read full Newsletter – PDF

.

.

.

.

February 2014 Edition

Gold rubics cube 500

Lead Article:

FROM ZERO TO HERO

It is estimated that 40% of venture-backed companies fail, 40% return moderate amounts of capital; and only 20% or less produce high returns. It’s the small percentage of high-return deals that are most responsible for the venture capital industry consistently performing above the public markets. So what separates the zeroes from the heroes? . . .

Read full Newsletter – PFD

.

.

.

.

November 2013 Edition

Dr. Alois Alzheimer - Wikipedia

Lead Article:

GOODBYE DR. ALZHEIMER

ADMdx has pioneered a new science to help big pharma wipe out Alzheimer’s disease. With a mission that large, they can pivot and adjust, yet never stray from their course.

Using computer learning, the company interprets patterns in brain scans not discerned by the naked eye. They diagnose early—before damage occurs, and help drug companies test new medicines with astonishing speed and accuracy.

ADMdx has already cleared all regulatory hurdles for the pharmaceutical application and enjoys significant barriers to entryin a $1B per year addressable market. They’re now ready for rapid growth. Add to that a dazzling staff, a lean business model, real revenue, and buyout prospects on the horizon.

In this interview, I’ve asked their CEO, Dawn Matthews, to explain her science at a kindergarten level so I’ll understand . . .

Read full Newsletter – PDF

.

.

TURN THE PAGE